Klaria Pharma Holding AB - Asset Resilience Ratio
Klaria Pharma Holding AB (KLAR) has an Asset Resilience Ratio of 0.84% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Klaria Pharma Holding AB to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Klaria Pharma Holding AB's Asset Resilience Ratio has changed over time. See Klaria Pharma Holding AB (KLAR) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Klaria Pharma Holding AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Klaria Pharma Holding AB.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr342.00K | 0.84% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr342.00K | 0.84% |
Asset Resilience Insights
- Limited Liquidity: Klaria Pharma Holding AB maintains only 0.84% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Klaria Pharma Holding AB Industry Peers by Asset Resilience Ratio
Compare Klaria Pharma Holding AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Klaria Pharma Holding AB (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Klaria Pharma Holding AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.84% | Skr342.00K ≈ $36.80K |
Skr40.77 Million ≈ $4.39 Million |
-0.21pp |
| 2024-12-31 | 1.04% | Skr598.00K ≈ $64.35K |
Skr57.27 Million ≈ $6.16 Million |
-0.67pp |
| 2023-12-31 | 1.71% | Skr1.25 Million ≈ $134.20K |
Skr72.95 Million ≈ $7.85 Million |
-12.23pp |
| 2022-12-31 | 13.94% | Skr16.76 Million ≈ $1.80 Million |
Skr120.27 Million ≈ $12.94 Million |
-7.61pp |
| 2021-12-31 | 21.55% | Skr25.49 Million ≈ $2.74 Million |
Skr118.31 Million ≈ $12.73 Million |
-2.06pp |
| 2020-12-31 | 23.60% | Skr31.25 Million ≈ $3.36 Million |
Skr132.41 Million ≈ $14.25 Million |
+20.74pp |
| 2019-12-31 | 2.87% | Skr2.92 Million ≈ $313.92K |
Skr101.73 Million ≈ $10.95 Million |
-4.62pp |
| 2018-12-31 | 7.49% | Skr7.96 Million ≈ $856.52K |
Skr106.25 Million ≈ $11.43 Million |
-3.48pp |
| 2017-12-31 | 10.97% | Skr17.10 Million ≈ $1.84 Million |
Skr155.87 Million ≈ $16.77 Million |
-8.22pp |
| 2016-12-31 | 19.19% | Skr31.10 Million ≈ $3.35 Million |
Skr162.03 Million ≈ $17.44 Million |
-- |
About Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; a… Read more